The Role of Blood Biomarker p-tau217 in the Early Detection of Alzheimer's Disease: A Systematic Review

Mangde Anata Sindhu

doi:10.47134/phms.v3i4.678

Authors

Mangde Anata Sindhu Universitas Warmadewa

DOI:

https://doi.org/10.47134/phms.v3i4.678

Keywords:

Alzheimer's disease, p-tau217, blood biomarker, early detection, systematic review

Abstract

This systematic review sought to assess the function of the blood biomarker phosphorylated tau 217 (p-tau217) in the early identification of Alzheimer's disease. A systematic review was carried out adhering to the PRISMA 2020 protocols. Literature searches were executed in PubMed, ScienceDirect, and Scopus to locate original studies published between 2023 and 2026. Eligible studies assessed blood p-tau217 in individuals with mild cognitive impairment, suspected Alzheimer's disease, Alzheimer's disease, or at-risk populations and reported diagnostic performance or correlations with established Alzheimer's biomarkers. Study quality was evaluated utilizing QUADAS-2 for diagnostic accuracy studies and the Study Quality Assessment Tools for observational and longitudinal studies. A total of 328 records were retrieved, of which 18 studies met the inclusion criteria. Research consistently demonstrates that plasma p-tau217 serves as a highly accurate biomarker for identifying the biological pathology of Alzheimer's disease, specifically regarding amyloid and tau status. Numerous studies have reported impressive area under the curve (AUC) scores between 0.92 and 0.97. When p-tau217 is paired with Aβ42 or the Aβ42/40 ratio, its diagnostic precision improves significantly, particularly in patients who are cognitively normal or in the preclinical stages of the disease.

References

Administration, U. S. F. and D. (2025). FDA clears first blood test used in diagnosing Alzheimer's disease. FDA.

Aguillon, D., Langella, S., Chen, Y., Sanchez, J. S., & Su, Y. (2023). Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease. Alzheimer's & Dementia, 19(6), 2585–2594. https://doi.org/10.1002/alz.12906

Ashton, N. J., Brum, W. S., & Di Molfetta, G. (2024). Diagnostic accuracy of a phosphorylated plasma tau 217 immunoassay for Alzheimer's disease pathology. JAMA Neurology, 81(3), 255–263. https://doi.org/10.1001/jamaneurol.2023.5319

Barthélemy, N. R., Horie, K., Sato, C., & Bateman, R. J. (2020). Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease. Journal of Experimental Medicine, 217(11), e20200861. https://doi.org/10.1084/jem.20200861

Chang, H. I., Ma, M. C., & Huang, K. L. (2025). Optimizing timing and cost-effective use of plasma biomarkers in Alzheimer's disease. Alzheimer's Research & Therapy, 17, 194. https://doi.org/10.1186/s13195-025-01851-2

Grande, G., Valletta, M., Rizzuto, D., et al. (2025). Blood-based biomarkers of Alzheimer’s disease and incident dementia in the community. Nature Medicine, 31, 2027–2035. https://doi.org/10.1038/s41591-025-03605-x

Janelidze, S., Barthélemy, N. R., & Salvadó, G. (2024). Plasma phosphorylated tau 217 and Aβ42/40 to predict early brain Aβ accumulation in people without cognitive impairment. JAMA Neurology, 81(9), 947–957. https://doi.org/10.1001/jamaneurol.2024.2619

Jack, C. R., Jr., Andrews, J. S., Beach, T. G., et al. (2024). Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimer’s & Dementia, 20(8), 5143–5169. https://doi.org/10.1002/alz.13859

Kang, H., Yoo, H., & Lee, J. (2025). Plasma phosphorylated tau 217 and amyloid-β 42/40 for amyloid risk in subgroups. Alzheimer's Research & Therapy, 17, 184. https://doi.org/10.1186/s13195-025-01826-3

Marsigit, J. (2025). The need for comprehensive palliative care. Acta Medica Indonesiana.

Martínez-Dubarbie, F., Guerra-Ruiz, A., & López-García, S. (2024). Longitudinal trajectory of plasma p-tau217 in cognitively unimpaired subjects. Alzheimer's Research & Therapy, 16, 268. https://doi.org/10.1186/s13195-024-01642-1

Martínez-Dubarbie, F., Guerra-Ruiz, A., & López-García, S. (2025). Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platform. Alzheimer's Research & Therapy, 17, 68. https://doi.org/10.1186/s13195-025-01719-5

Matsuura, S., Tagai, K., & Tatebe, H. (2026). Comparison of three plasma p-tau217 assays to detect PET-confirmed Alzheimer's pathologies. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. https://doi.org/10.1002/dad2.70294

Niimi, Y., Janelidze, S., & Sato, K. (2024). Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly. Alzheimer's Research & Therapy, 16, 115. https://doi.org/10.1186/s13195-024-01469-w

World Health Organization. (2025). Dementia. WHO.

Palmqvist, S., Janelidze, S., Quiroz, Y. T., et al. (2020). Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA, 324(8), 772–781. https://doi.org/10.1001/jama.2020.12134

Palmqvist, S., Tideman, P., Cullen, N., et al. (2021). Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures. Nature Medicine, 27, 1034–1042. https://doi.org/10.1038/s41591-021-01348-z

Palmqvist, S., Tideman, P., & Mattsson-Carlgren, N. (2024). Blood biomarkers to detect Alzheimer's disease in primary care and secondary care. JAMA, 332(15), 1245–1257. https://doi.org/10.1001/jama.2024.13855

Rissman, R. A., Donohue, M. C., & Langford, O. (2024). Longitudinal phospho-tau217 predicts amyloid positron emission tomography in asymptomatic Alzheimer's disease. The Journal of Prevention of Alzheimer's Disease, 11(4), 823–830. https://doi.org/10.14283/jpad.2024.134

Rissman, R. A., Langford, O., & Raman, R. (2024). Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease. Alzheimer's & Dementia, 20(2), 1214–1224. https://doi.org/10.1002/alz.13542

Salvadó, G., Janelidze, S., & Bali, D. (2025). Phosphorylated plasma tau 217 to identify preclinical Alzheimer's disease. JAMA Neurology, 82(11), 1122–1134. https://doi.org/10.1001/jamaneurol.2025.3217

Sim, M. A., Rowsthorn, E., & O'Brien, W. T. (2025). Plasma phosphorylated tau-217 correlates with brain atrophy, cognition, and cerebrospinal fluid biomarkers in a cognitively healthy community cohort. Brain Communications, 7, fcaf383. https://doi.org/10.1093/braincomms/fcaf383

Therriault, J., Brum, W. S., & Trudel, L. (2025). Blood phosphorylated tau for the diagnosis of Alzheimer's disease: A systematic review and meta-analysis. The Lancet Neurology, 24(9), 740–752. https://doi.org/10.1016/S1474-4422(25)00227-3

Thijssen, E. H., La Joie, R., Strom, A., et al. (2021). Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: A retrospective diagnostic performance study. The Lancet Neurology, 20(9), 739–752. https://doi.org/10.1016/S1474-4422(21)00214-3

Um, Y. H., Wynveen, P., & Holland, M. (2025). Neuroimaging correlates and biomarker performance of a fully automated plasma p-tau217/Aβ42 ratio assay in a clinical cohort with Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70942

Vanderlip, C. R., Gillen, D. L., Grill, J. D., & Stark, C. E. L. (2026). Digital memory assessments and plasma pTau217 enable efficient preclinical Alzheimer's trials. The Journal of Prevention of Alzheimer's Disease. https://doi.org/10.1016/j.tjpad.2026.100503

Wang, J., Fan, D. Y., & Huang, S. (2025). Performance of blood biomarkers in internal jugular vein for Alzheimer's disease pathologies: The Delta Method study. Science Bulletin, 70, 4061–4069. https://doi.org/10.1016/j.scib.2025.10.044

Wang, J., Huang, S., & Lan, G. (2025). Diagnostic accuracy of plasma p-tau217/Aβ42 for Alzheimer's disease in clinical and community cohorts. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70038